EHA 2017 | Using vaccines to impart a long-term response in lenalidomide-treated MM
Ivan Marques Borrello, MD, from the John Hopkins School of Medicine, Baltimore, MD, USA, describes the potential of applying vaccines following chemotherapy to impart a long-term therapeutic response in patients with multiple myeloma (MM). One such vaccine, GVAX, will soon undergo a randomised trial in combination with lenalidomide, compared to lenalidomide alone, on patients with MM who are undergoing a lenalidomide regimen. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up